|
公司基本資料信息
|
中文名稱:阿法替尼雜質(zhì),達(dá)比加群酯雜質(zhì)對(duì)照品標(biāo)準(zhǔn)品
英文名稱:Afatinib Impurity,Dabigatran Impurity
規(guī)格:10mg/25mg/50mg/100mg等多種規(guī)格可選。
用途:實(shí)驗(yàn)研發(fā),藥品申報(bào)檢測(cè),不得用于臨床醫(yī)學(xué)診斷。
隨貨提供:所有雜質(zhì)對(duì)照品均隨貨提供HPLC,NMR,MS圖譜及CoA證書。
保存及取用:為了防止產(chǎn)品含量降低,應(yīng)防潮,避光和抗氧化包裝,保存應(yīng)以提高物質(zhì)穩(wěn)定性為原則。如果一次使用很少量,可以將其適當(dāng)分裝后使用,這樣可以有效的防止試劑污染。請(qǐng)不要在臟亂和強(qiáng)光環(huán)境中取用,以免造成污染和失效。
阿法替尼雜質(zhì),達(dá)比加群酯雜質(zhì)對(duì)照品標(biāo)準(zhǔn)品 雜質(zhì)列表:
Afatinib | (S,E)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide |
Afatinib Impurity 1 | (S)-N-(3-chloro-4-fluorophenyl)-6-nitro-7-((tetrahydrofuran-3-yl)oxy)quinazolin-4-amine |
Afatinib Impurity 2 | (S)-N4-(3-chloro-4-fluorophenyl)-7-((tetrahydrofuran-3-yl)oxy)quinazoline-4,6-diamine |
Afatinib Impurity 3 | (R,E)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide |
Afatinib Impurity 4 | (S,E)-N-(4-((3,4-dichlorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide |
Afatinib Impurity 5 | (S,E)-N-(4-((3,4-difluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide |
Afatinib Impurity 6 | (S,E)-N-(4-((4-chloro-3-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide |
Afatinib Impurity 7 | (S,E)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)but-2-enamide |
Afatinib Impurity 8 | (S,E)-4-bromo-N-(4-((3-chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)but-2-enamide |
Afatinib Impurity 9 | (S,E)-4-(dimethylamino)-N-(4-hydroxy-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)but-2-enamide |
Afatinib Impurity 10 | (S,E)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(methylamino)but-2-enamide |
Afatinib Impurity 11 | |
Afatinib Impurity 12 | 1-(4-((3-chloro-4-fluorophenyl)amino)-7-(((S)-tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-5-hydroxypyrrolidin-2-one |
Dabigatran | 3-(2-(((4-carbamimidoylphenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoic acid |
Dabigatran Impurity 1 | ethyl 3-(2-(iminomethyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate |
Dabigatran Impurity 2 | 3-(2-(((4-(N-((hexyloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoic acid |
Dabigatran Impurity 3 | ethyl 3-(1-methyl-3-oxo-N-(pyridin-2-yl)-1,2,3,4-tetrahydroquinoxaline-6-carboxamido)propanoate |
Dabigatran Impurity 4 | methyl 3-(2-(hydroxymethyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate |
Dabigatran Impurity 5 | 3-(2-(chloromethyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoic acid |
Dabigatran Impurity 6 | diethyl 3,3'-((2,2'-(oxybis(methylene))bis(1-methyl-1H-benzo[d]imidazole-5,5'-carbonyl))bis(pyridin-2-ylazanediyl))dipropanoate |
Dabigatran Impurity 7 | hexyl (imino(4-(((1-methyl-5-(pyridin-2-ylcarbamoyl)-1H-benzo[d]imidazol-2-yl)methyl)amino)phenyl)methyl)carbamate |
Dabigatran Impurity 8 | (Z)-3-(2-(((4-(N'-((hexyloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoic acid |
Dabigatran Impurity 9 | ethyl 3-(2-(((4-(((hexyloxy)carbonyl)carbamoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate |
Dabigatran Impurity 10 | (Z)-ethyl 3-(2-(((4-(N'-((hexan-2-yloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate |
Dabigatran Impurity 11 | (Z)-ethyl 3-(2-(((4-(N'-((hexan-3-yloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate |
Dabigatran Impurity 12 | ethyl 3-(1,2-dimethyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate |
Dabigatran Impurity 13 | ethyl 3-(1-methyl-2-oxo-N-(pyridin-2-yl)-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamido)propanoate |
Dabigatran Impurity 14 | (Z)-ethyl 2-(((4-(N'-((hexyloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-1H-benzo[d]imidazole-5-carboxylate |
Dabigatran Impurity 15 | ethyl 3-(2-(((4-cyanophenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate |
Dabigatran Impurity 16 | ethyl 3-(2-(((4-(ethoxy(imino)methyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate hydrochloride |
Dabigatran Impurity 17 | (Z)-methyl 3-(2-(((4-(N'-((hexyloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate |
Dabigatran Impurity 18 | (Z)-hexyl (amino(4-(((5-((3-amino-3-oxopropyl)(pyridin-2-yl)carbamoyl)-1-methyl-1H-benzo[d]imidazol-2-yl)methyl)amino)phenyl)methylene)carbamate |
Dabigatran Impurity 19 | ethyl 3-(2-(((4-carbamoylphenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate |
Dabigatran Impurity 20 | ethyl 3-(2-(((4-carbamimidoylphenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate hydrochloride |
Dabigatran Impurity 21 | ethyl 3-(3-amino-4-(methylamino)-N-(pyridin-2-yl)benzamido)propanoate |
Dabigatran Impurity 22 | ethyl 3-(3-(2-((4-cyanophenyl)amino)acetamido)-4-(methylamino)-N-(pyridin-2-yl)benzamido)propanoate |
若雜質(zhì)列表中未有您需要的雜質(zhì),歡迎來(lái)電或在線詳詢,產(chǎn)品庫(kù)時(shí)常會(huì)有更新,另外,我司有專業(yè)研發(fā)團(tuán)隊(duì),可提供部分雜質(zhì)定制服務(wù),以最大可能的滿足您對(duì)雜質(zhì)對(duì)照品的選購(gòu)需求。
阿法替尼雜質(zhì),達(dá)比加群酯雜質(zhì)對(duì)照品標(biāo)準(zhǔn)品 訂購(gòu)方式:
聯(lián)系人:何先生
手機(jī):15012456311
QQ:781007885
郵箱:phastandards@gmail.com
歡迎您通過(guò)電話,電郵或在線客服向我司詢價(jià)及訂購(gòu)產(chǎn)品。
阿法替尼雜質(zhì),達(dá)比加群酯雜質(zhì)對(duì)照品標(biāo)準(zhǔn)品 作用機(jī)理:
阿法替尼是一種口服藥物,是表皮生長(zhǎng)因子受體(EGFR)和人表皮受體2(HER2)酪氨酸激酶的不可逆抑制劑。Ⅱb/Ⅲ期隨機(jī)研究表明,與安慰劑+最佳支持治療相比,阿法替尼+最佳支持治療治療既往一二線化療及EGFR-TKI治療失敗的非小細(xì)胞肺癌患者,未改善患者總生存,但顯著改善了無(wú)進(jìn)展生存期,提高了ORR和8周疾病控制率。另一項(xiàng)研究(LUX-LUNG2)結(jié)果顯示,伴有常見(jiàn)EGFR突變類型的大多數(shù)(61%)患者接受阿法替尼治療后,腫瘤顯著縮小、腫瘤進(jìn)展時(shí)間較晚、生存期較長(zhǎng)。這些結(jié)果初步證實(shí)阿法替尼是比較有前途的靶向藥物。
阿法替尼為不可逆轉(zhuǎn)的ErbB家族阻斷劑,能抑壓信息傳導(dǎo)和阻隔與癌細(xì)胞生長(zhǎng)和分裂相關(guān)的主要通道。由于通過(guò)ErbB家族信息傳導(dǎo)機(jī)制可由多個(gè)同二聚體跟異二聚體引發(fā),所以同時(shí)抑制多個(gè)ErbB家族成員(如 EGFR, HER2, ErbB3 及 ErbB4),能較有效地中斷下游信息傳導(dǎo)。
達(dá)比加群酯是最前沿的新一代口服抗凝藥物直接凝血酶抑制劑(DTIs),用于預(yù)防非瓣膜性房顫患者的卒中和全身性栓塞。達(dá)比加群酯可提供有效的、可預(yù)測(cè)的、穩(wěn)定的抗凝效果,同時(shí)較少發(fā)生藥物相互作用,無(wú)藥物食物相互作用,無(wú)需常規(guī)進(jìn)行凝血功能監(jiān)測(cè)或劑量調(diào)整。
阿法替尼雜質(zhì),達(dá)比加群酯雜質(zhì)對(duì)照品標(biāo)準(zhǔn)品 深圳遠(yuǎn)揚(yáng)專注醫(yī)藥標(biāo)準(zhǔn)品,雜質(zhì)對(duì)照品,更多產(chǎn)品,歡迎選購(gòu)(篇幅有限,只列舉了一小部分,更多更全,請(qǐng)來(lái)電詳詢):
雜質(zhì)對(duì)照品部分產(chǎn)品列表:
法羅培南雜質(zhì),氯丁替諾雜質(zhì),溴麥角環(huán)肽雜質(zhì),吉格列汀雜質(zhì),替米沙坦雜質(zhì),番瀉苷ABCD,維蘭特羅雜質(zhì),非那沙星雜質(zhì),卡巴拉汀雜質(zhì),福沙匹坦異構(gòu)體,艾沙康唑雜質(zhì),頭孢泊肟酯雜質(zhì),噻嗎洛爾雜質(zhì),鹽酸拓?fù)涮婵惦s質(zhì),利培酮雜質(zhì),富馬酸福莫特羅雜質(zhì),雷莫拉寧雜質(zhì),碘帕醇雜質(zhì),卡巴他賽雜質(zhì),克林霉素雜質(zhì),依普利酮雜質(zhì),鹽酸伊立替康雜質(zhì),納曲酮雜質(zhì),喹法米特雜質(zhì),維羅非尼雜質(zhì),阿德福韋酯雜質(zhì),伊伐布雷定雜質(zhì),鹽酸奧洛他定雜質(zhì),CO-1686雜質(zhì),鹽酸米諾環(huán)素雜質(zhì),纈沙坦雜質(zhì),特拉匹韋雜質(zhì),卡博替尼雜質(zhì),普萘洛爾雜質(zhì),氨曲南雜質(zhì),替普瑞酮雜質(zhì),佐米曲普坦雜質(zhì),鹽酸多塞平雜質(zhì),豆甾醇雜質(zhì),依普沙坦雜質(zhì),帕利哌酮雜質(zhì),多柔比星雜質(zhì),雷馬曲班雜質(zhì),哌唑嗪雜質(zhì),達(dá)比加群酯雜質(zhì),恩雜魯胺雜質(zhì),托法替布雜質(zhì),達(dá)泊西汀雜質(zhì),鹽酸環(huán)苯扎林雜質(zhì),溴隱亭雜質(zhì),沙丁胺醇雜質(zhì),鹽酸氯哌斯丁雜質(zhì),阿扎胞苷雜質(zhì),阿立哌唑雜質(zhì),美普他酚雜質(zhì),度魯特韋雜質(zhì),莫匹羅星雜質(zhì),蝶酸雜質(zhì)
本頁(yè)面所展現(xiàn)的信息: 阿法替尼雜質(zhì),達(dá)比加群酯雜質(zhì)對(duì)照品標(biāo)準(zhǔn)品 ,該信息的真實(shí)性、準(zhǔn)確性、合法性由該信息的發(fā)布方: 深圳遠(yuǎn)揚(yáng)化學(xué)技術(shù)有限公司 完全負(fù)責(zé)。生化分析儀器網(wǎng)對(duì)此不承擔(dān)任何保證責(zé)任。
友情提醒 :
建議您在購(gòu)買相關(guān)產(chǎn)品前務(wù)必確認(rèn) 深圳遠(yuǎn)揚(yáng)化學(xué)技術(shù)有限公司 的資質(zhì)及產(chǎn)品質(zhì)量,過(guò)低的價(jià)格有可能是虛假信息,請(qǐng)謹(jǐn)慎對(duì)待,謹(jǐn)防欺詐行為。
如您發(fā)現(xiàn)該信息內(nèi)有任何違法/侵權(quán)信息,請(qǐng)立即向我們舉報(bào)并提供有效線索。
QQ:918700790